This observational retrospective analysis will provide useful information for clinicians and payers, and local guidelines committee members, to improve the understanding of Cytomegalovirus clinical and economic burden and clinical management of pediatric patients undergoing allogeneic Hematopoietic Stem Cells Transplantation in Italy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Summary of demographic and baseline characteristics
Timeframe: at baseline (day of transplant)
CMV Seroprevalence in the under 18 population undergoing allogeneic HSCT
Timeframe: at baseline (day of transplant)
CMV serostatus
Timeframe: at baseline (day of transplant)
Donor type
Timeframe: at baseline (day of transplant)
Stem cell source
Timeframe: at baseline (day of transplant)
Conditioning intensity
Timeframe: at baseline (day of transplant)
Underlying condition
Timeframe: at baseline (day of transplant)
Usage of immunosuppression
Timeframe: at baseline (day of transplant)
Current standard of care in CMV management in terms of PET approach
Timeframe: during the first-year post-transplant
Current standard of care in CMV management in terms of GCV prophylaxis
Timeframe: during the first-year post-transplant
Current standard of care in CMV management in terms of ACV prophylaxis
Timeframe: during the first-year post-transplant
Current standard of care in CMV management in terms of other
Timeframe: during the first-year post-transplant